AstraZeneca Q4 revenue just shy of analyst estimates

AstraZeneca Q4 revenue just shy of analyst estimates

LONDON (Reuters) – AstraZeneca on Thursday posted fourth-quarter revenue just shy of analyst estimates, with slightly lower-than-expected sales of its best-selling oncology and rare blood disorder drugs.

The London-listed drugmaker, which reports its results in U.S. dollars, reported an adjusted profit of 1.38 cents per share on sales of about $11.2 billion.

Analysts were expecting $1.34 per share on sales of about $11.3 billion, according to company-compiled consensus estimates.

AstraZeneca forecast adjusted earnings per share in 2023 to grow by a “high single digit to low double-digit percentage”, and revenue to increase by a “low-to-mid single-digit percentage”, at constant currency rates.

(Reporting by Natalie Grover and Maggie Fick; editing by Jason Neely)

US Stock Market Struggling While Microsoft Jumps and Alphabet Stumbles in Battle of AI GiantsSilver Price Forecast – Silver Rallies Ever So SlightlyGerman Inflation Ticks Up but Not Sufficiently to Spook InvestorsEUR/USD, GBP/USD, USD/CAD, USD/JPY – U.S. Dollar Gains Ground After Williams CommentsAUDUSD Forecast – Rebounding Ahead of US Initial Claims, RBA Quarterly OutlookBTC Fear & Greed Index Avoids Neutral Despite the Fed HawksLoadingLoadingLoading